eligibility_summary
Eligibility: Adults (>=18) with RT (DLBCL or Hodgkin) from CLL/SLL, new or relapsed, measurable disease, ECOG 0-2, adequate counts (ANC >=1000, Plt >=30K, Hgb >=8), liver/renal function, controlled HBV/HCV, contraception, able to take oral meds/start allopurinol. Exclude prior PD-1 for RT, venetoclax-refractory, recent therapy incl CAR-T/transplant/investigational, CYP3A inhibitors/inducers, active autoimmune disease/infection, HIV, malabsorption, serious comorbidity, pregnancy/nursing.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II (withdrawn) trial testing: 1) Venetoclax—oral small-molecule BCL‑2 inhibitor, restores apoptosis in BCL‑2–dependent malignant B cells. 2) Rituximab—chimeric anti‑CD20 monoclonal antibody, depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement activation, and direct apoptotic signaling. 3) Nivolumab—anti‑PD‑1 IgG4 monoclonal antibody, blocks PD‑1 to release T‑cell inhibition and enhance antitumor immunity. Targets/pathways: malignant B cells in Richter’s transformation (DLBCL/Hodgkin variant) arising from CLL/SLL, BCL‑2 survival pathway, CD20 on B cells, PD‑1/PD‑L1 immune checkpoint with downstream T‑cell activation. Exploratory biomarkers include MRD (blood/marrow), PD‑1/PD‑L1 expression, T‑cell subsets, and CLL genetics (TP53, IgVH, FISH).